To evaluate the synergistic effect of IL-11/GP130 suppression with conventional chemotherapeutic drugs, oxaliplatin, which was approved by FDA for the treatment of colon cancer, was selected in combination with bazedoxifene. The gene discussed is IL11; the disease is malignant colon neoplasm.